***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 SEPTEMBER 2022**

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Eptifibatide | The sponsor requested the delisting of Inegrillin® (eptifibatide) from the Pharmaceutical Benefits Scheme.  The PBAC noted the products were being discontinued by the sponsor and that there were available clinical alternatives. The PBAC advised the delisting of this drug would not result in an unmet clinical need. |

**Signature of Judy Tran, 
Acting Director, PBAC Assessment Section, Office of Health Technology Assessment, Technology Assessment and Access Division
**

Judy Tran

Acting Director

PBAC Assessment Section

Office of Health Technology Assessment

Technology Assessment and Access Division

12 August 2022